Aimmune Therapeutics, Inc. today announced the pricing of its initial
public offering of 10,000,000 shares of its common stock at a public
offering price of $16.00 per share, before underwriting discounts and
commissions. In addition, Aimmune has granted the underwriters a 30-day
option to purchase up to an additional 1,499,999 shares of common stock
at the same price. Aimmune's common stock is expected to begin trading
on The NASDAQ Global Select Market on August 6, 2015 under the symbol
AIMT.
The offering is expected to close on August 11, 2015, subject to
satisfaction of customary closing conditions.
BofA Merrill Lynch, Credit Suisse and Piper Jaffray are acting as joint
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in